Trendlines’ shares in BioSight were acquired by Arkin Bio Ventures Ltd. in June 2017. 

BioSight develops advanced therapeutics to enable safe and effective treatment for life-threatening diseases and to improve the quality of life for patients with cancer and related diseases.

The Product & Technology

BioSight’s pipeline of targeted chemotherapy pro-drugs target cancer cells and release active chemotherapy drugs inside the cancer cells while significantly minimizing the toxicity associated with conventional chemotherapy treatments.

Astarabine™, the company’s lead proprietary product is in clinical stages for the treatment of leukemia.

The Team

  • Ruth Ben Yakar, Ph.D.,CEO: More than 22 years’ experience in the biomedical field, including 14 years of management in the biotech industry, leading diverse corporate, business, operational, financial, clinical and regulatory development, and research activities; former CEO, Procognia, a public biotech company
  • Stela Gengrinovitch, Ph.D., Co-Founder and CSO: More than 20 years of experience in cell biology, enzymology, and biochemistry; Ph.D., M.Sc., B.Sc., biochemistry, Technion-Israel Institute of Technology
  • Mark Gengrinovitch, LLB, Co-Founder and CFO: More than 25 years’ experience in engineering and management; formerly, mechanical engineer at Elbit Systems; LLB, Ono University; B.Sc., mechanical engineering, Technion-Israel Institute of Technology; B.Ed., Haifa University


Stage: Revenue
Founded: 2000

In the Media

BioSight logo card

Font Resize